LQDA Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of -520.57% compared to Liquidia's net margin of -10571.43%. Liquidia's return on equity of -168.37% beat AIM ImmunoTech's return on equity of -256.33%.

Liquidia has a consensus price target of $25.33, signalling upside risk potential of 71.06%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 1967.67%. Given that AIM ImmunoTech has higher upside potential than Liquidia, analysts believe AIM ImmunoTech is more attractive than Liquidia.

Liquidia has a beta of 0.074, which suggesting that the stock is 92.603% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.411, suggesting its less volatile than the S&P 500 by 58.887%.

Liquidia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Liquidia quarterly revenues are $4.4M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Liquidia's net income of -$23.2M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Liquidia's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia is 70.16x versus 36.55x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals has a net margin of -520.57% compared to Liquidia's net margin of --. Liquidia's return on equity of -168.37% beat Armata Pharmaceuticals's return on equity of --.

Liquidia has a consensus price target of $25.33, signalling upside risk potential of 71.06%. On the other hand Armata Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 246.02%. Given that Armata Pharmaceuticals has higher upside potential than Liquidia, analysts believe Armata Pharmaceuticals is more attractive than Liquidia.

Liquidia has a beta of 0.074, which suggesting that the stock is 92.603% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.887, suggesting its less volatile than the S&P 500 by 11.295%.

Liquidia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Liquidia quarterly revenues are $4.4M, which are larger than Armata Pharmaceuticals quarterly revenues of --. Liquidia's net income of -$23.2M is lower than Armata Pharmaceuticals's net income of -$5.5M. Notably, Liquidia's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia is 70.16x versus 732.91x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Curis has a net margin of -520.57% compared to Liquidia's net margin of -344.32%. Liquidia's return on equity of -168.37% beat Curis's return on equity of -461.34%.

Liquidia has a consensus price target of $25.33, signalling upside risk potential of 71.06%. On the other hand Curis has an analysts' consensus of -- which suggests that it could grow by 621.65%. Given that Curis has higher upside potential than Liquidia, analysts believe Curis is more attractive than Liquidia.

Liquidia has a beta of 0.074, which suggesting that the stock is 92.603% less volatile than S&P 500. In comparison Curis has a beta of 3.490, suggesting its more volatile than the S&P 500 by 249.021%.

Liquidia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Curis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia pays -- of its earnings as a dividend. Curis pays out -- of its earnings as a dividend.

Liquidia quarterly revenues are $4.4M, which are larger than Curis quarterly revenues of $2.9M. Liquidia's net income of -$23.2M is lower than Curis's net income of -$10.1M. Notably, Liquidia's price-to-earnings ratio is -- while Curis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia is 70.16x versus 1.65x for Curis. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -520.57% compared to Liquidia's net margin of 18.02%. Liquidia's return on equity of -168.37% beat Protalix BioTherapeutics's return on equity of -29.54%.

Liquidia has a consensus price target of $25.33, signalling upside risk potential of 71.06%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 522.32%. Given that Protalix BioTherapeutics has higher upside potential than Liquidia, analysts believe Protalix BioTherapeutics is more attractive than Liquidia.

Liquidia has a beta of 0.074, which suggesting that the stock is 92.603% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.611%.

Liquidia has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Liquidia pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Liquidia quarterly revenues are $4.4M, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Liquidia's net income of -$23.2M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Liquidia's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Liquidia is 70.16x versus 4.01x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.